Invention Grant
US09376425B2 Heterocyclic compounds as MDM2 inhibitors for the treatment of cancer
有权
杂环化合物作为治疗癌症的MDM2抑制剂
- Patent Title: Heterocyclic compounds as MDM2 inhibitors for the treatment of cancer
- Patent Title (中): 杂环化合物作为治疗癌症的MDM2抑制剂
-
Application No.: US14347628Application Date: 2012-09-26
-
Publication No.: US09376425B2Publication Date: 2016-06-28
- Inventor: Michael D. Bartberger , Hilary Plake Beck , Xiaoqi Chen , Richard Victor Connors , Jeffrey Deignan , Jason A. Duquette , John Eksterowicz , Brian M. Fox , Jiasheng Fu , Ana Gonzalez Buenrostro , Felix Gonzalez Lopez De Turiso , Darin J. Gustin , Julie A. Heath , Michael G. Johnson , Frank Kayser , David John Kopecky , Yihong Li , Zhihong Li , Zhihua Ma , Joel McIntosh , Julio C. Medina , Jeffrey Thomas Mihalic , Steven H. Olson , Yosup Rew , Philip M. Roveto , Michael J. Schmitt , Daqing Sun , Xiaodong Wang , Malgorzata Wanska , Christine Weathers , Xuelei Yan
- Applicant: AMGEN INC.
- Applicant Address: US CA Thousand Oaks
- Assignee: Amgen, Inc.
- Current Assignee: Amgen, Inc.
- Current Assignee Address: US CA Thousand Oaks
- Agent Markus Bergauer; Elsa D. Lemoine
- International Application: PCT/US2012/057389 WO 20120926
- International Announcement: WO2013/049250 WO 20130404
- Main IPC: C07D265/06
- IPC: C07D265/06 ; C07D413/04 ; C07D413/10 ; C07D417/04 ; C07D413/12 ; C07D265/32
Abstract:
The present invention provides MDM2 inhibitor compounds of Formula I or II, or the pharmaceutically acceptable salts thereof, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.
Public/Granted literature
- US20140235629A1 HETEROCYCLIC COMPOUNDS AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER Public/Granted day:2014-08-21
Information query
